Fig. 1

Targeting vaccine Ags to Clec9A generates long-lasting enhanced Ab responses. a Schematic representation of rat anti-Clec9A-Ag 10B4 constructs b Schematic representation of the vaccination strategy. C57BL/6 mice were injected i.v. with 2 μg anti-Clec9A-M2e mAb construct (clone 10B4), 2 μg isotype control-M2e mAb construct (clone GL117), 2 μg anti-Clec9A-SP70 mAb construct, or 2 μg isotype control-SP70 mAb construct in the absence or presence of adjuvant, 5 nmol CpG-1668. A group of mice were injected with PBS as unprimed control. At day 42 after priming, all groups of mice were boosted with 2 μg anti-Clec9A-M2e mAb construct or with 2 μg anti-Clec9A-SP70 mAb construct. Serum samples were collected at the indicated times post immunisation and Ag-specific IgG responses measured by ELISA. c Targeted versus (vs.) untargeted anti-M2e responses. d Targeted vs. untargeted anti-SP70 responses. e The anti-rat Ig response associated with c. f The anti-rat Ig response associated with d. Each point represents the geometric mean end point titre with 95% confidence interval (CI) from a group of five mice. The dotted line in c and d represents a “maximal” response obtained in separate experiments by injection of C57BL/6 mice with 50 μg KLH-Ag in Freund’s complete adjuvant followed by boosting with 50 μg KLH-Ag in Freund’s incomplete adjuvant and sampling the blood 30 days later. This full kinetic experiment was carried out once (n = 5 mice per group) but the results were confirmed at restricted time points in two other experiments